15Jul
14Jul
OpenText launches Carbonite Endpoint backup for India market
OpenText has announced the launch of Carbonite Endpoint backup solution in India, with the added option for businesses to securely backup their data into a local vault to meet data compliances. Read more >>
12Jul
DeepLook, Inc.’s Segmentation and Measurement Tool Captures FDA Clearance
Connecticut-based software firm DeepLook, Inc., announced Thursday it has received U.S. Food & Drug Administration approval for DL Precise, its one-click segmentation and measurement tool. Read more >>
09Jul
Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate
Today, Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced positive results from a 60-subject, open-label, Phase I trial of AKS-452, its protein subunit, room temperature stable, COVID-19 vaccine candidate. Read more >>
09Jul
PlateletBio Names Derek Adams, Ph.D., as Chief Operating Officer
PlateletBio, a private cell therapy company focused on developing a suite of allogeneic cell therapeutics based on a platform of platelet-like cells (PLCs), today announced that Derek Adams has joined the company as its Chief Operating Officer (COO). Read more >>
08Jul
ZetrOZ Systems’ Medical Devices to Heal Injuries Are Proudly Made in the USA
As the country celebrates its birthday on Independence Day, ZetrOZ Systems, developers of the Sustained Acoustic Medicine (SAM) wearable ultrasound device, proudly announces that virtually all elements of its products are sourced and manufactured in the United States. Read more >>
07Jul
S’More, New Anti-Superficial Dating App
A new dating app is looking to give you some more options when it comes to looking for love. It's called S'More. Read more >>
07Jul
New vaccines should help India fill gaps in vaccination campaign
...One such vaccine is the AKS-452 jab developed by US-based Akston Biosciences, which is currently undergoing Phase I/II trials in the Netherlands. Read more >>
01Jul
Corbus Pharmaceuticals Expands Pipeline with Two New mAbs
Corbus Pharmaceuticals has licensed two integrin-targeting mAbs, expanding its therapeutics pipeline into inflammatory, fibrotic, and metabolic diseases as well as cancer. Read more >>
30Jun